Issues

Cell-free DNA (cfDNA) methylation patterns were used to determine that leukocytes, rather than neoplastic cells or surrounding normal epithelial cells, generally contributed to the excess cfDNA found in patients with cancer.

The presence of cell-free tumor DNA was reported in breast milk from patients with breast cancer, and its use as a screening method surpassed plasma liquid biopsy in terms of detecting and molecularly profiling early-stage tumors, even prior to diagnosis.

A biobank of colorectal cancer organoids with matched cancer-associated fibroblasts was generated and serves as a preclinical model that can determine the impact of the tumor microenvironment on transcriptomic subtypes and sensitivity to therapeutic drugs.

Patients with head and neck squamous cell carcinoma that responded to dual PD-1/CTLA4 immune checkpoint blockade exhibited a parallel remodeling of the activated CD4⁺ regulatory T-cell (Treg) and dysfunctional CD8⁺ T-cell compartments.

Inhibiting the catalytic activity of METTL3 revealed potent antitumor activity both as a single agent and in combination with anti–PD-1 therapy, providing preclinical rationale for targeting RNA methylation as a potential immunotherapeutic approach.

An inflammatory checkpoint generated by mRNA splicing of IL1RN can inhibit a mutant KRAS–mediated inflammatory cascade, tumor progression, and resistance to immunotherapy in cholangiocarcinoma, providing a potential therapeutic option for KRAS-mutant cancers.

The neurotransmitter GABA was identified as a mediator of functional communication within the melanoma microenvironment, which highlights the role of electrical activity in melanoma initiation and suggests GABA as a potential therapeutic target in this disease.